TABLE 1.

Virologic characteristics of the 11 subjects with virologic failure^a

Subject	APL dose (mg)	Visitb	Population tropism	RT/PRO mutations	CD4 count (cells/mm3)c	CD4 count change (cells/mm3)	Log10 HIV-1 RNA (c/ml)c	HIV-1 RNA change (c/ml)	APL FCIC50 (fold)	APL MPI (%)
P1	200 BID	Day 1	R5		77		6.256		0.90	98.8
		Week 20	R5	WT	NT	NT	4.360	−1.896	1.37	97.5
P2	400 BID	Day 1	R5	K103N	365		4.652		0.53	95.0
		Week 8	R5	K103N	606	241	4.987	0.335	0.64	91.6
P3	800 QD	Day 1	R5		124		5.121		0.76	97.3
		Week 16	DM	WT	162	38	4.260	−0.861	0.92	93.3
P4	800 QD	Day 1	R5		175		5.885		1.09	99.5
		Week 4	R5	WT	218	43	5.860	−0.025	1.11	99.8
P5	800 QD	Day 1	R5		125		4.654		0.66	72.5
		Week 12	DM	WT	122	−3	4.583	−0.071	1.36	70.7
P6	800 QD	Day 1	R5		172		4.619		0.77	98.4
		Week 4	R5	WT	284	112	4.356	−0.263	0.67	99.0
P7	800 QD	Day 1	R5	M41L	334		5.481		0.80	99.6
		Week 20	R5	M41L	363	29	5.405	−0.076	0.77	99.2
P8	400 BID	Day 1	DM	NA	187		4.889		0.30	99.5
		Week 4	DM	NA	213	26	4.918	0.029	0.18	99.7
P9	800 QD	Day 1	R5	NA	617		4.107		1.23	96.9
		Week 12	R5	NA	1182	565	3.528	−0.579	0.62	93.9
P10d	200 BID	Day 1	DM		109		5.624		0.75	96.9
		Week 12	DM	WT	178	69	5.667	0.043	0.73	98.6
P11	—e	Day 1	R5	K103N	342		5.243		0.57	99.0
		Week 20	R5	K103N	564	222	3.511	−1.732	0.95	98.2

^aNA, value could not be determined; NT, not tested; WT, wild-type sequence detected.

^bVisits other than on day 1 indicate the virologic failure time point.

^cSingle value per time point, determined as described in Materials and Methods.

^dSubject was DM-tropic at enrollment.

^eSubject received lamivudine-zidovudine/LPV-r without APL.